Esperion Gains Ground as Bempedoic Acid Endorsed in Key PAD/Diabetes Guidelines
Event summary
- Esperion’s bempedoic acid has been recommended as a first-line therapy for LDL-C lowering in patients with peripheral artery disease (PAD) and diabetes within the 2025 ACC Scientific Statement.
- The recommendation highlights bempedoic acid’s proven cardiovascular and limb benefits, particularly for patients already taking maximally tolerated statins.
- Data from the 2024 AHA Scientific Sessions, analyzing major adverse limb events (MALE) in the CLEAR Outcomes trial, showed a 36% reduction with bempedoic acid compared to placebo.
- Esperion anticipates further endorsement of bempedoic acid in forthcoming U.S. dyslipidemia treatment guidelines from ACC/AHA in early 2026.
The big picture
This endorsement represents a significant validation of Esperion’s bempedoic acid, positioning it as a crucial therapy for a large and underserved patient population. The prevalence of diabetes and PAD creates a substantial market opportunity, but the success of bempedoic acid will depend on its ability to overcome existing treatment barriers and demonstrate sustained clinical benefit. The ACC’s recommendation provides a strong foundation for Esperion to expand its commercial footprint and potentially attract further investment.
What we're watching
- Guideline Adoption
- The speed with which clinicians incorporate the ACC’s recommendation into practice will be a key driver of bempedoic acid adoption and Esperion’s revenue growth.
- Regulatory Landscape
- The forthcoming ACC/AHA guidelines in early 2026 will be critical; a favorable inclusion could significantly expand bempedoic acid’s market reach.
- Competitive Dynamics
- How competitors respond to this endorsement, particularly in terms of pricing and marketing strategies, will shape the long-term competitive landscape for LDL-C lowering therapies.
Related topics